pd 1 resistant head and neck cancer epidemiology forecast insight

DelveInsight’s ‘PD-1 Resistant Head and Neck Cancer – Epidemiology Forecast – 2034’ report deliver an in-depth understanding of and historical and forecasted epidemiology of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, South Korea, and Taiwan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• China
• South Korea
• Taiwan

Study Period: 2021-2034

PD-1 Resistant Head and Neck Cancer Disease Understanding

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease encompassing various tumors that originate in the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx. The disease group as a whole is associated with different epidemiology, etiology, and therapy. Worldwide, it represents the sixth most common neoplasia and accounts for 6% of all cases, being responsible approximately for 1–2% of tumor deaths. Given the complexities of head and neck cancer (HNC), treatment decisions have to be taken by multidisciplinary teams (MDTs) with training not only in treatment but also in supportive care (considering swallowing, nutritional, dental, and voice impairment due to the effects of clinical intervention).

The three main types of treatment for managing head and neck cancer were radiation therapy, surgery, and chemotherapy. However, the survival rate for head and neck cancer is quite low due to its ability to evade the immune response. Immune escape and T-cell exhaustion are mechanisms used by Head and Neck cancer for cancer survival in the tumor microenvironment. Several immune checkpoint inhibitors have been approved for cancer which has significantly improved the survival rate. However, they are associated with various side effects. Hence, the current approach focuses on novel therapeutics that can also bypass the mechanism that leads to relapse in this cancer while improving the survival rate.

PD-1 Resistant Head and Neck Cancer Epidemiology

The PD-1 Resistant Head and Neck Cancer epidemiology division provide insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Key Findings

The total incident cases of PD-1 Resistant Head and Neck Cancer patients are increasing in the studied geography during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted PD-1 Resistant Head and Neck Cancer symptoms epidemiology segmented as the Head and Neck Cancer diagnoses patients, PD-1 treated patients and PD-1 refractory patients. The report includes the prevalent scenario of PD-1 Resistant Head and Neck Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea and Taiwan from 2021 to 2034.

Country-Wise PD-1 resistant patients Epidemiology

The epidemiology segment also provides the IO treated patients epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea and Taiwan.

• The total cases of PD-1 resistant patients in the covered geographies were 11,940 in 2020.
• As per the estimates, the United States has the largest population of PD-1 resistant patients.
• Among the EU5 countries, France had the highest cases of PD-1 resistant patients. On the other hand, Spain had the lowest cases of PD-1 resistant patients in 2020.

Scope of the Report

• The PD-1 Resistant Head and Neck Cancer report cover a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The PD-1 Resistant Head and Neck Cancer epidemiology report and model provide an overview of PD-1 Resistant Head and Neck Cancer’s risk factors and global trends in the ten major markets (US, France, Germany, Italy, Spain, UK, Japan, China, South Korea and Taiwan).
• The report provides insight into PD-1 Resistant Head and Neck Cancer’s historical and forecasted patient pool in ten major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, China, South Korea and Taiwan.
• The report helps to recognize the growth opportunities in the covered geographies concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of PD-1 Resistant Head and Neck Cancer.
• The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by Head and Neck cancer diagnosed patients in 7MM, China, South Korea and Taiwan.
• The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by PD-1 treated patients in 7MM, China, South Korea and Taiwan.
• The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by PD-1 refractory patients in 7MM, China, South Korea and Taiwan.

Report Highlights

• 10-year Forecast of PD-1 Resistant Head and Neck Cancer epidemiology
• 7MM, China, South Korea and Taiwan Coverage
• Head and Neck cancer diagnosed patients.
• PD-1 treated patients.
• PD-1 resistant patients.

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the covered geographies7MM, China, South Korea and Taiwan for the patient population about PD-1 Resistant Head and Neck Cancer?
• What are the key findings of the PD-1 Resistant Head and Neck Cancer epidemiology across 7MM, China, South Korea and Taiwan, and which country will have the highest number of patients during the study period (2021-2034)?
• What would be the total number of PD-1 Resistant Head and Neck Cancer patients across 7MM, China, South Korea and Taiwan during the study period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2021-2034)?
• At what CAGR the patient population is expected to grow in 7MM, China, South Korea and Taiwan during the study period (2021-2034)?
• What are the disease risk, burdens, and unmet needs of PD-1 Resistant Head and Neck Cancer?
• What are the currently available treatments for PD-1 Resistant Head and Neck Cancer?

Reasons to buy

The PD-1 Resistant Head and Neck Cancer epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global PD-1 Resistant Head and Neck Cancer market.
• Quantify patient populations in the global PD-1 Resistant Head and Neck Cancer market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD-1 Resistant Head and Neck Cancer therapeutics in each of the markets covered.
• Understand the magnitude of the PD-1 Resistant Head and Neck Cancer population by its diagnosed cases.
• Understand the magnitude of the PD-1 Resistant Head and Neck Cancer population by PD-1 treated patients.
• Understand the magnitude of the PD-1 Resistant Head and Neck Cancer population by PD-1 resistant patients.
• The PD-1 Resistant Head and Neck Cancer epidemiology report and model were written and developed by masters and Ph.D. level epidemiologists.
• The PD-1 Resistant Head and Neck Cancer epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population